Clovis Oncology, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2021-12-09: Study NCT05180162; Company role Collaborator; Phase Phase 1; Status Completed.
- 2021-04-15: Study NCT04151563; Company role Collaborator; Phase Phase 1, Phase 2; Status Withdrawn.
- 2020-11-05: Study NCT04624178; Company role Collaborator; Phase Phase 2; Status Active not recruiting.
- 2020-07-29: Study NCT04539327; Company role Collaborator; Phase Observational; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2021-12-09 | NCT05180162 Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286 | Collaborator Lead: Thomas Hope | Phase 1 | Completed | Liver Fibrosis; Pulmonary Fibrosis; Myocardial Fibrosis | 16 | 2024-05-28 |
| 2021-04-15 | NCT04151563 A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Collaborator Lead: Bristol-Myers Squibb | Phase 1, Phase 2 | Withdrawn | Carcinoma, Non-small Cell Lung Cancer | 0 | 2026-05-13 |
| 2020-11-05 | NCT04624178 A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | Collaborator Lead: Memorial Sloan Kettering Cancer Center | Phase 2 | Active not recruiting Results posted | Leiomyosarcoma | 20 | 2026-11-16 |
| 2020-07-29 | NCT04539327 Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study | Collaborator Lead: Grupo Español de Investigación en Cáncer de Ovario | Observational | Completed Results posted | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | 51 | 2021-07-31 |
| 2020-06-08 | NCT04227522 Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | Collaborator Lead: North Eastern German Society of Gynaecological Oncology | Phase 3 | Completed | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Clear Cell Carcinoma | 42 | 2024-07-01 |
| 2020-04-03 | NCT04253262 A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | Collaborator Lead: Brown University | Phase 1, Phase 2 | Active not recruiting | Metastatic Castration-resistant Prostate Cancer | 13 | 2027-01 |
| 2020-01-09 | NCT03995017 Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma | Collaborator Lead: University of Kansas Medical Center | Phase 1, Phase 2 | Unknown | Esophagus Cancer, Adenocarcinoma; Stomach Cancer, Adenocarcinoma | 34 | 2024-12 |
| 2019-09-04 | NCT03958045 Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | Collaborator Lead: Zhonglin Hao | Phase 2 | Completed Results posted | Small Cell Lung Cancer | 33 | 2022-11-15 |
| 2019-08-09 | NCT03899155 Pan Tumor Rollover Study | Collaborator Lead: Bristol-Myers Squibb | Phase 2 | Recruiting | Cancer | 1,500 | 2029-08-25 |
| 2019-07-29 | NCT04042116 A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | Lead sponsor | Phase 1, Phase 2 | Suspended | Advanced Solid Tumor; Gynecologic Cancer | 227 | 2024-01 |
| 2019-07-19 | NCT03694262 The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | Collaborator Lead: Medical College of Wisconsin | Phase 2 | Completed Results posted | Endometrial Cancer; Uterine Carcinosarcoma | 30 | 2026-03-10 |
| 2019-05-20 | NCT03533946 Rucaparib in Nonmetastatic prOstAte With BRCAness | Collaborator Lead: University of Utah | Phase 2 | Terminated Results posted | Prostate Cancer | 7 | 2023-01-12 |
| 2019-03-06 | NCT03617679 Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | Collaborator Lead: University of Colorado, Denver | Phase 2 | Completed Results posted | Metastatic Endometrial Cancer | 79 | 2026-02-27 |
| 2019-01-28 | NCT03654833 Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma | Collaborator Lead: University of Leicester | Phase 2 | Completed Results posted | Mesothelioma, Malignant | 186 | 2024-03-15 |
| 2018-12-24 | NCT03559049 Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | Collaborator Lead: University of Michigan Rogel Cancer Center | Phase 1, Phase 2 | Terminated Results posted | Stage IV Non-small Cell Lung Cancer | 25 | 2025-05-01 |
| 2018-09-10 | NCT03413995 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations | Collaborator Lead: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Completed Results posted | Prostate Cancer Metastatic | 12 | 2024-09-12 |
| 2018-08-14 | NCT03572478 Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | Collaborator Lead: University of Chicago | Phase 1, Phase 2 | Terminated Results posted | Prostate Cancer; Endometrial Cancer | 12 | 2020-10-01 |
| 2018-07-12 | NCT03552471 Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Collaborator Lead: Ohio State University Comprehensive Cancer Center | Phase 1 | Completed | BRCA1 Gene Mutation; BRCA2 Gene Mutation; Folate Receptor Alpha Positive; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Serous Carcinoma; Recurrent Uterine Carcinosarcoma; Platinum Resistant Ovarian Cancer | 25 | 2022-12-19 |
| 2018-06-29 | NCT03476798 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium | Collaborator Lead: University of Oklahoma | Phase 2 | Completed Results posted | Cervical Cancer; Endometrial Cancer | 49 | 2023-09-29 |
| 2018-05-23 | NCT03542175 A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy | Collaborator Lead: Memorial Sloan Kettering Cancer Center | Phase 1 | Completed Results posted | Breast Cancer | 31 | 2025-09-10 |
| 2018-01-12 | NCT03318445 Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | Collaborator Lead: Pamela Munster | Phase 1 | Completed | Solid Tumor, Unspecified, Adult | 22 | 2021-03-01 |
| 2017-12-19 | NCT03338790 An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | Collaborator Lead: Bristol-Myers Squibb | Phase 2 | Completed Results posted | Prostate Cancer | 292 | 2025-01-10 |
| 2017-04 | NCT02747797 Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations | Collaborator Lead: Teresa Helsten, MD | Phase 2 | Withdrawn | Advanced Cancer | 0 | 2022-04 |
| 2016-11-29 | NCT02935634 A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer | Collaborator Lead: Bristol-Myers Squibb | Phase 2 | Completed Results posted | Advanced Gastric Cancer | 190 | 2022-05-11 |
| 2016-11-10 | NCT02873962 A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | Collaborator Lead: Dana-Farber Cancer Institute | Phase 2 | Active not recruiting Results posted | Peritoneal Cancer; Ovarian Cancer; Fallopian Tube Cancer | 72 | 2027-01 |
| 2016-05 | NCT02705339 Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | Collaborator Lead: Washington University School of Medicine | Phase 2 | Withdrawn | Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Nonsmall Cell Lung Cancer | 0 | 2020-04 |
| 2016-03 | NCT02505048 A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature | Collaborator Lead: UNICANCER | Phase 2 | Completed | Metastatic Breast Cancer | 41 | 2019-12 |
| 2016-02-24 | NCT02630186 A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Non-small Cell Lung Cancer | 3 | 2017-09-05 |
| 2015-09-30 | NCT02580708 Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer | Lead sponsor | Phase 1, Phase 2 | Terminated | Non-small Cell Lung Cancer | 7 | 2016-06-27 |
| 2015-02 | NCT02678182 Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | Collaborator Lead: Royal Marsden NHS Foundation Trust | Phase 2 | Active not recruiting | Adenocarcinoma of the Oesophagus; Adenocarcinoma of the Gastro-oesophageal Junction; Adenocarcinoma of the Stomach | 494 | 2027-06 |
| 2015-02 | NCT02322281 TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | Lead sponsor | Phase 3 | Terminated Results posted | Non-small Cell Lung Cancer | 149 | 2018-03-29 |
| 2014-11 | NCT02186301 TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy | Lead sponsor | Phase 2, Phase 3 | Terminated Results posted | Non-Small Cell Lung Cancer | 100 | 2017-06-28 |
| 2014-09-09 | NCT02202746 A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | Lead sponsor | Phase 2 | Terminated Results posted | Breast Cancer; Metastatic Breast Cancer; MBC; HER2 Positive; HER2; Estrogen Receptor Positive; ER; Triple Negative | 178 | 2017-01-18 |
| 2014-06-16 | NCT02147990 Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer | Lead sponsor | Phase 2 | Terminated Results posted | Non-small Cell Lung Cancer | 318 | 2019-08-27 |
| 2014-04 | NCT02109016 A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations | Lead sponsor | Phase 2 | Terminated | Non-Small Cell Lung Cancer; Squamous Non-Small Cell Lung Cancer; NSCLC; Small Cell Lung Cancer; SCLC; Lung Cancer; Advanced Lung Cancer; Metastatic Lung Cancer; Stage IV Lung Cancer | 18 | 2016-09 |
| 2012-07 | NCT01641575 A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin | Lead sponsor | Phase 1 | Terminated | Solid Tumor; Non-small-cell Lung Cancer; Lung Cancer | 8 | 2013-06 |
| 2012-03-27 | NCT01526928 Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Locally Advanced or Metastatic Non Small Cell Lung Cancer | 612 | 2018-08-27 |
| 2011-04 | NCT01392976 Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors | Lead sponsor | Phase 1 | Completed | Advanced Solid Tumor | 17 | 2013-04 |
| 2011-04 | NCT01233375 Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | Lead sponsor | Phase 2 | Completed | Metastatic Pancreatic Adenocarcinoma | 19 | 2013-03 |
| 2010-05 | NCT01124786 A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) | Lead sponsor | Phase 2 | Completed Results posted | Metastatic Pancreatic Adenocarcinoma | 367 | 2013-06 |
| 2010-02 | NCT01074970 PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | Collaborator Lead: Hoosier Cancer Research Network | Phase 2 | Completed Results posted | Breast Cancer | 135 | 2018-12-15 |
| NCT02547675 Rociletinib (CO-1686) USA Expanded Access Program | Lead sponsor | Expanded_access | No longer available | Non-small Cell Lung Cancer |